Postmenopozal Hastalarda Hormon Tedavisi ve Diğer Antirezorbtif Ajanların Kullanım Yaygınlığı ve Etkilerinin Karşılaştırılması,

Öz

Anahtar Kelimeler

• -

Postmenopozal Hastalarda Hormon Tedavisi ve Diğer Antirezorbtif Ajanların Kullanım Yaygınlığı ve Etkilerinin Karşılaştırılması,

Öz

Amaç: Bu çalımada amaç kliniğimize başvuran menopoz hastalarının hormon tedavisi ve diğer antirezorbtif ajanları kullanım yaygınlığını araştırmaktır. Ayrıca hasta- ların kemik mineral yoğunlukları ve mamografi bulguları da değerlendirilmiştir. Gereç ve yöntem: Bu çalışma, menopoz hastalarının dosyaları taranarak yapılan retrospektif bir araştırmadır. Has- taların demografik özellikleri, kemik mineral yoğunluğu ve dansiteleri, aldıkları tedaviler ve mamografileri incelenmiştir. İstatistiksel analizde t-test, tek yön ANOVA ve çift değişken korelasyon analizi kullanılmıştır (p0,05). Hormon tedavisi alanlar ve almayanlar arasında mamografik bulgular açısından anlamlı fark saptanmadı (p>0,05). Sonuç: Kliniğimizde hormon tedavisi tercih edilen hasta grubunun büyük bir kısmını osteoporozu olmayan hastalar oluşturmaktadır. Osteoporozu olanlarda ise hormon tedavisi veya diğer antirezorbtifler hastanın kliniğine göre benzer oranda tercih edilmektedir. Hormon tedavisi almış olmanın mamografik bulgulara etkisi saptanma- mıştır

Anahtar Kelimeler

• Osteoporoz, menopoz, hormon tedavisi, antirezorbtif tedavi

Kaynakça

1. 1. Speroff L, Fritz MA. Clinical Gynecologic Endocrinology and Infertility: 7nd eds, chapter, 2005; 16-18.
2. 2. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen / Progestin Interventions (PEPI) trial. JAMA 1996; 276:1389-1396.
3. 3. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
4. 4. US Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2002; 137: 834-839.
5. 5. Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: Results of two randomized double-blind, placebo-controlled, dose finding studies. J Clin Endocrinol Metab 2001; 86: 4717-4726.
6. 6. Rymer J. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss. Osteoporos İnt 2001; 12: 478-483.
7. 7. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Anoud C. A controlled trial of raloxifene HCI; impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996;11;835-842.
8. 8. Shelly W, Draper MW, Krishnan V, Wong M, Jafffe RB. Selective Estrogen Receptor Modulators: An update on Recent Clinical Findings. Obstet Gynecol survey 2008; 63; 163-181.

9. 9. Black DM, Cummings SR, Karpf DM et al. Fracture İntervention Trial Research Group, Randomized trial effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348:1535-1541.
10. 10. Hosking D, Chilvers CED, Christiansen C et al. Early Postmenopausal İntervention Cohort Study Group, Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. New Eng J Med 1998; 338: 485-492.
11. 11. Brown JP, Kendler DL, Mc Clung MR et al. The efficacy and tolerability of risedronate once a week for the The treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 103-111.
12. 12. Hasling C, Charles P, Jensen FT, Mosekilde L. Calcium metabolism in postmenopausal osteoporosis: the influence of dietary calcium and net absorbed calcium. J Bone Min Res 1990; 5: 939-946.
13. 13. Tilyard MW, Spears GFS, Thompson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. New Eng J Med 1992; 326: 357-362.
14. 14. Fioretti P, Gambacciani M, Taponeco F, Melis GB, Capelli N, Spinetti. Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women. Maturitas 1992; 15: 225-232.
15. 15. Chesnut CH, Silverman S, Adriano K et al. Randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109: 267- 276.
16. 16. Marie PJ, Hott M, Modrowski D et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorbtion and maintaining bone formation in estrogen deficient rats. J Bone Miner Res 1993; 8: 607-615.
17. 17. Chow RK, Harrison JE, Brown CF, Hajek V. Physical fitness effect on bone mass in postmenopausal women. Arch Phys Med Rehabil 1986; 67: 231- 234. 18. Hopper JL, Seeman E. The bone density of female twins discordant for tobacco use. New Engl J Med 1994; 330: 430-431.
18. 19. Chlebowski RT, Hendrix SL, Langer RD et al. WHI Investigators, Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women’s Health Initiative Randomized Trial. JAMA 2003; 289: 3243-3253.
19. 20. McKinlay SM, Brambilla DJ, Posner JG. Smoking and age at menopause. Ann Intern Med 1985; 103: 350-356.
20. 21. Gold EB, Bromberger J, Crawford S et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001;153: 865-874.
21. 22. Hassa H. Uzmanlık Sonrası Eğitim ve Güncel Gelişmeler. TJOD 2004; 1: 39-50.
22. 23. Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Rec Prog Horm Res 2002; 57: 385-409.
23. 24. Liel Y, Kraus S, Levy J, Shany S. Evidence that estrogens modulate activity and increase the number of 1,25- dihydroxyvitamin D receptors in osteoblast-like cells (ROS 17/2.8). Endocrinology 1992; 130: 2597-2601.
24. 25. Sırola J, Kröger H, Honkanen R et al. Factors affecting bone loss around menopause in women without HT: a prospective study. Maturitas 2003; 45: 159-167.
25. 26. Komulainen MH, Kröger H, Tuppurainen MT et al. HT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas 1998; 31: 45- 54.
26. 27. Mosekilde L, Beck-Nielsen H, Sorensen OH et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women- results of Danish Osteoporosis Prevention Study. Maturitas 2000; 36: 181-193.
27. 28. Cauley J, Robbins J, Chen Z et al. Women’s Health Initiative Investigators, Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women’s Health Initıative Randomized Trial. JAMA 2003; 290:1729-1738.
28. 29. Lindsay R,Gallgher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287: 2668-2676.
29. 30. Lindsay R, MacLean A, Kraszewski A, Clark AC, Garwood J. Bone response to termination of estrogen treatment. Lancet 1978; 24: 1325-1327.
30. 31. Brown JP, Josse RG. The Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167: S1- 34.
31. 32. Dogan E, Posaci C. Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women. Postgrad Med J 2002; 78: 727-31.
32. 33. Posaci C, Altunyurt S, Islekel H et al. The values of urinary NTx in postmenopausal women undergoing HRT; the role of additional alendronate therapy. Maturitas 2002; 42: 281- 286.
33. 34. Fournier A, Berrino F, Chapelon FC. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107: 103–111.